Stock listing
LSE:0VGI TG Therapeutics, Inc. Share Price
UK listing (LSE) of TG Therapeutics, Inc. · home listing NASDAQ:TGTX
Follow TG Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:TGTX
$59.95 USD -1.23 (-2.0%)
Close on Nov 2, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:TGTX
- Day range
- $59.59 – $63.60 USDNov 2, 2026
- Volume
- 2.57M sharesNov 2, 2026
- Market cap
- $9.18B USDAt the close on Nov 2, 2026 · price × 153.1M shares outstanding
- 52-week range
- $26.76 – $63.60 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $101.2M USDMedian day 1.61M shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TGTX · Home | $59.95 USD | -1.23 (-2.0%) | 2,574,106 | $61.01 | $63.60 | $59.59 | $61.18 | Close on Nov 2, 2026 |
| Frankfurt:NKB2 | €54.80 EUR | +6.80 (+14.2%) | — | €51.20 | €54.80 | €51.20 | €48.00 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:TGTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $59.95 | -1.23 | -2.0% | $61.01 | $63.60 | $59.59 | 2,574,106 | |
| $61.18 | +3.10 | +5.3% | $58.15 | $61.76 | $58.00 | 2,847,689 | |
| $58.08 | +0.68 | +1.2% | $57.81 | $58.96 | $56.93 | 1,788,450 | |
| $57.40 | +0.96 | +1.7% | $55.84 | $57.46 | $55.67 | 929,360 | |
| $56.44 | +1.65 | +3.0% | $54.10 | $57.08 | $53.90 | 1,484,829 | |
| $54.79 | +0.62 | +1.1% | $54.81 | $55.49 | $53.71 | 1,187,437 | |
| $54.17 | +1.01 | +1.9% | $52.56 | $55.81 | $51.83 | 1,978,100 | |
| $53.16 | -0.04 | -0.1% | $53.02 | $53.70 | $52.53 | 1,289,200 | |
| $53.20 | -1.33 | -2.4% | $54.51 | $54.95 | $52.73 | 1,178,000 | |
| $54.53 | +1.23 | +2.3% | $53.36 | $55.32 | $53.08 | 1,056,700 | |
| $53.30 | -0.67 | -1.2% | $54.35 | $54.97 | $52.90 | 1,550,100 | |
| $53.97 | -2.03 | -3.6% | $56.00 | $56.25 | $53.66 | 1,771,600 | |
| $56.00 | +1.63 | +3.0% | $55.12 | $56.83 | $54.76 | 1,808,500 | |
| $54.37 | +0.03 | +0.1% | $54.08 | $55.37 | $53.36 | 1,285,300 | |
| $54.34 | -0.93 | -1.7% | $55.23 | $55.39 | $53.63 | 1,001,200 | |
| $55.27 | -0.10 | -0.2% | $55.38 | $55.86 | $54.65 | 758,100 | |
| $55.37 | +2.03 | +3.8% | $53.72 | $55.46 | $53.36 | 1,620,400 | |
| $53.34 | +0.39 | +0.7% | $53.34 | $53.90 | $52.12 | 1,735,100 | |
| $52.95 | +0.76 | +1.5% | $51.83 | $53.88 | $51.41 | 1,506,200 | |
| $52.19 | -1.72 | -3.2% | $54.11 | $54.11 | $51.34 | 2,412,200 | |
| $53.91 | -0.38 | -0.7% | $54.35 | $54.75 | $53.32 | 1,545,900 | |
| $54.29 | +0.67 | +1.2% | $54.17 | $54.98 | $53.15 | 1,650,500 | |
| $53.62 | -2.16 | -3.9% | $55.58 | $56.12 | $53.59 | 2,119,900 | |
| $55.78 | -0.41 | -0.7% | $56.41 | $56.98 | $55.36 | 1,908,200 | |
| $56.19 | 0.00 | 0.0% | $56.04 | $56.68 | $54.79 | 1,607,100 | |
| $56.19 | -1.24 | -2.2% | $57.35 | $57.66 | $55.88 | 1,442,300 | |
| $57.43 | -0.09 | -0.2% | $57.97 | $58.69 | $56.61 | 1,308,900 | |
| $57.52 | +1.52 | +2.7% | $55.95 | $57.55 | $55.09 | 1,138,200 | |
| $56.00 | -2.11 | -3.6% | $58.11 | $58.25 | $54.78 | 2,119,700 | |
| $58.11 | +0.95 | +1.7% | $57.41 | $58.62 | $56.56 | 2,084,200 | |
| $57.16 | +0.29 | +0.5% | $57.23 | $58.92 | $56.00 | 2,142,600 | |
| $56.87 | +0.40 | +0.7% | $56.98 | $57.73 | $56.18 | 5,169,000 | |
| $56.47 | +0.62 | +1.1% | $57.61 | $57.87 | $56.04 | 1,468,000 | |
| $55.85 | +2.81 | +5.3% | $53.12 | $57.61 | $53.11 | 2,349,800 | |
| $53.04 | -0.96 | -1.8% | $53.59 | $54.41 | $52.50 | 1,758,100 | |
| $54.00 | +0.11 | +0.2% | $53.97 | $54.20 | $53.19 | 1,362,200 | |
| $53.89 | -1.50 | -2.7% | $55.71 | $56.26 | $53.47 | 1,367,500 | |
| $55.39 | +0.74 | +1.4% | $54.36 | $55.41 | $54.01 | 1,367,400 | |
| $54.65 | -1.09 | -2.0% | $55.55 | $57.14 | $54.24 | 1,409,800 | |
| $55.74 | -0.245 | -0.4% | $55.34 | $55.93 | $54.09 | 1,085,500 | |
| $55.99 | -0.725 | -1.3% | $56.30 | $56.70 | $55.56 | 992,400 | |
| $56.71 | -0.19 | -0.3% | $57.40 | $58.47 | $56.19 | 1,571,300 | |
| $56.90 | +0.81 | +1.4% | $56.18 | $57.87 | $54.70 | 2,360,500 | |
| $56.09 | +1.79 | +3.3% | $53.00 | $56.27 | $52.11 | 3,197,600 | |
| $54.30 | +0.37 | +0.7% | $53.58 | $54.36 | $52.67 | 1,622,100 | |
| $53.93 | -1.79 | -3.2% | $55.53 | $55.53 | $53.83 | 1,030,700 | |
| $55.72 | +0.69 | +1.3% | $55.00 | $55.97 | $54.15 | 1,222,000 | |
| $55.03 | -0.39 | -0.7% | $55.50 | $56.04 | $54.53 | 963,200 | |
| $55.42 | -0.59 | -1.1% | $56.66 | $57.90 | $54.68 | 1,991,544 | |
| $56.01 | +1.74 | +3.2% | $53.19 | $56.49 | $52.00 | 2,847,159 | |
| $54.27 | +3.71 | +7.3% | $51.10 | $56.87 | $49.97 | 5,558,340 | |
| $50.56 | -1.13 | -2.2% | $51.65 | $53.18 | $50.52 | 2,435,627 | |
| $51.69 | +1.43 | +2.8% | $51.62 | $52.34 | $50.71 | 1,289,534 | |
| $50.26 | +0.98 | +2.0% | $49.28 | $50.29 | $48.98 | 1,195,008 | |
| $49.28 | +0.54 | +1.1% | $48.74 | $49.80 | $48.50 | 1,062,873 | |
| $48.74 | +0.80 | +1.7% | $47.27 | $48.93 | $47.27 | 1,073,489 | |
| $47.94 | -1.56 | -3.2% | $49.70 | $49.70 | $47.53 | 2,769,549 | |
| $49.50 | -0.40 | -0.8% | $50.00 | $50.55 | $49.34 | 2,017,944 | |
| $49.90 | +0.74 | +1.5% | $49.29 | $50.35 | $49.00 | 1,500,779 | |
| $49.16 | -0.60 | -1.2% | $49.26 | $50.00 | $48.50 | 1,912,351 | |
| $49.76 | +0.21 | +0.4% | $49.96 | $50.19 | $49.11 | 1,768,460 | |
| $49.55 | -0.33 | -0.7% | $49.99 | $50.60 | $49.47 | 1,404,802 | |
| $49.88 | +1.145 | +2.3% | $48.22 | $50.03 | $48.22 | 2,841,382 | |
| $48.74 | +2.565 | +5.6% | $46.16 | $49.00 | $45.37 | 2,865,716 | |
| $46.17 | -5.86 | -11.3% | $51.06 | $52.65 | $45.82 | 6,409,871 |
- Ticker
- LSE:0VGI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Oct 23, 2026
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
Latest earnings call · Aug 3, 2026
TG Therapeutics (NASDAQ:TGTX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 23, 2026
10th Joint ACTRIMS-ECTRIMS Meeting 2026
Conference · 15 slides
Calls
Upcoming
TG Therapeutics (NASDAQ:TGTX) Q3 2026 Earnings Call
Mon, Nov 09, 2026 · 8:30 AM ET
Register
Replays
TG Therapeutics (NASDAQ:TGTX) Q2 2026 Earnings Call
Mon, Aug 03, 2026 · 8:30 AM ET
Watch TranscriptTG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Call
Wed, May 06, 2026 · 8:30 AM ET
Watch TranscriptTG Therapeutics (NASDAQ:TGTX) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 8:30 AM ET
Watch Transcript
Latest news
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
Oct 23, 2026
Closed $54.17 (+1.9%) on Oct 23, 2026
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
Oct 21, 2026
Closed $53.20 (-2.4%) on Oct 21, 2026
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
Oct 12, 2026
Closed $55.27 (-0.2%) on Oct 12, 2026
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Oct 8, 2026
Closed $53.34 (+0.7%) on Oct 8, 2026
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $55.39 (+1.4%) on Sep 10, 2026
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
Aug 3, 2026
Closed $46.17 (-11.3%) on Aug 3, 2026
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
Jul 29, 2026
Closed $53.48 (-2.5%) on Jul 29, 2026
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
Jul 6, 2026
Closed $55.47 (+4.1%) on Jul 6, 2026
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
Jun 9, 2026
Closed $43.37 (+5.9%) on Jun 9, 2026
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
Jun 3, 2026
Closed $40.11 (+9.5%) on Jun 3, 2026
Decks
10th Joint ACTRIMS-ECTRIMS Meeting 2026
Conference · 15 slides · Oct 23, 2026
J.P. Morgan Healthcare Conference 2025
Conference · 21 slides · January 2025
Technical Presentation (October 2021)
Technical · 22 slides · October 2021
Technical Presentation (September 2021)
Technical · 15 slides · September 2021
TG Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 233 in all · newest Oct 23, 2026 · oldest 2019
- Calls
- 24 calls with a replay · 24 with a transcript · latest Aug 3, 2026
- Decks
- 19 decks · latest Oct 23, 2026
Where TG Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TGTX · Home listing | NASDAQ | United States | USD |
| gettex:NKB2 | gettex | Germany | EUR |
| LS Exchange:A1JXW7 | LS Exchange | Germany | EUR |
| Tradegate:NKB2 | Tradegate | Germany | EUR |
| BOATS:TGTX | BOATS | United States | USD |
| Lang & Schwarz:A1JXW7 | Lang & Schwarz | Germany | EUR |
| Milan:1TGTX | Milan | Italy | EUR |
| Frankfurt:NKB2 | Frankfurt | Germany | EUR |
| LSE:0VGI · This page | LSE | United Kingdom | USD |
| BX Swiss:NKB2 | BX Swiss | Switzerland | CHF |
| Dusseldorf:NKB2 | Dusseldorf | Germany | EUR |
| Hamburg:NKB2 | Hamburg | Germany | EUR |
| Munich:NKB2 | Munich | Germany | EUR |
| Stuttgart:NKB2 | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about TG Therapeutics, Inc.